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Abstract
Background: In Germany, antenatal influenza vaccination is recommended since 2010, but uptake remains low.
Several countries recently introduced antenatal pertussis vaccination, which is currently under consideration in
Germany. We conducted a survey among gynaecologists on attitudes, practices and barriers regarding influenza
and pertussis vaccination during pregnancy.
Methods: Gynaecologists were invited to complete a pre-tested, 24-item questionnaire published in the German
Professional Association of Gynaecologists’ journal in September 2017 within 2 months. Associations between
variables were examined using Chi-Squared, Fischer’s Exact or t-tests. Variables associated with gynaecologists’ self-
reported implementation of vaccination in pregnant women were identified using univariate and multivariate
logistic regression analyses.
Results: Of 867 participants (response 11%), 91.4 and 59.4% reported currently vaccinating pregnant women
against influenza and pertussis, respectively. Gynaecologists who reported obtaining annual influenza vaccination
and actively informing their patients about these vaccinations were significantly more likely to vaccinate pregnant
women against influenza (96.5% vs. 65.7 and 95.1% vs. 62.2%) and pertussis (63.1% vs. 44.3 and 82.4% vs. 12.9%).
Performing influenza vaccination was least likely among gynaecologists who perceived logistical difficulties as a
vaccination barrier (35.9%), while pertussis vaccination was least likely if the lacking official recommendation (32.0%),
logistical difficulties (27.1%), safety concerns (17.5%) and limited vaccine effectiveness (11.1%) were perceived as
barriers. Of participants not yet vaccinating pregnant women against pertussis, 86.5% reported they would follow
an official recommendation. Including vaccination recommendations in the maternity record (95.2%) and informing
the public (88.7%) and health care professionals (86.6%) were considered the most suitable measures to achieve
high pertussis vaccination coverage.
Conclusions: The large proportion reporting performance of influenza vaccination during pregnancy and high
acceptance of a potential recommendation for pertussis vaccination reflected positive attitudes towards vaccination
among participants. However, factors associated with failure to vaccinate may be more prevalent among non-
participants. Results suggest that gynaecologists’ confidence in vaccination is crucial for implementing vaccination
in pregnancy. Thus, doubts on vaccine effectiveness and safety should be allayed among gynaecologists and
pregnant women via various communication channels, and solutions for logistical barriers sought. Including
antenatal vaccination recommendations in the maternity record would serve as an important reminder for both
groups.
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Background
Influenza vaccination during pregnancy
In Germany, 5 to 20% of the population contracts sea-
sonal influenza annually [1]. In several studies pregnant
women had more severe disease than other adults [2–4],
with a 7- to 9-fold increased risk for hospitalisation dur-
ing the 2009 influenza pandemic [5, 6] as well as later
influenza seasons [7]. Infants are also at increased risk
for severe disease and complications such as otitis media
and pneumonia [2]. Therefore, in 2010, the German
Standing Committee on Vaccination (STIKO) recom-
mended influenza vaccination for pregnant women from
the second trimester of pregnancy, or in case of an
underlying chronic disease, from the first trimester on-
wards [2, 8], with the goal of protecting mothers as well
as infants. Influenza vaccines are not licensed for infants
until 6 months of age. Thus, maternal vaccination aims
to reduce the risk of transmission to the infant from the
mother (cocooning) on the one hand and confer passive
immunity in the first weeks of life on the other. A recent
review of randomized clinical trials found evidence that
maternal vaccination reduced the incidence of laboratory
confirmed influenza both in mothers and their infants
[9]. Despite these benefits, according to the most recent
data available from Germany, influenza vaccination up-
take remained low at 11 to 23% in women who were
pregnant during the influenza seasons of 2012/13 and
2013/14 [10–13]. This was similar to the 24% median vac-
cination coverage for the influenza season 2014/15 among
eight reporting EU member states, but lower to the re-
ported coverage in the United Kingdom (44–56%) [14].
Pertussis in infants and pertussis vaccination during
pregnancy
As in many western countries [15], the pertussis dis-
ease burden in Germany remains substantial despite
high vaccination coverage in children [16, 17]. This is
at least partly explained by lower effectiveness of cur-
rently available acellular vaccines versus previously
available whole cell vaccines [18] and rapidly waning
immunity [19]. Incidence is highest in infants too
young to be vaccinated, who are also at highest risk
for life-threatening complications, such as pneumonia,
seizures, pulmonary hypertension and hypoxic en-
cephalopathy [15, 20, 21]. A recent study in Germany
during a period of lower disease activity in 2013–
2015 estimated the incidence of pertussis requiring
hospitalization in infancy at 50 cases/100,000 infants
[22]. In epidemic years, this number is likely to be 2
to 3 times higher. From 2013 to 2016, 58% of all
infants with pertussis reported to the national com-
municable disease notification system and 83% of
those younger than 3 months of age were reported to
be hospitalized [17]. Of 7 pertussis-related deaths
reported from 2013 to 2017, 3 were in infants (case
fatality: 0.2%), the remainder in persons over 60 years
of age [23].
Pertussis vaccination is recommended by STIKO for
all infants from 2months of age [24]. Unless vaccinated
in the last 10 years, STIKO recommends pertussis vaccin-
ation for women of child-bearing age, women postpartum
and close household contacts of infants (preferably by 4
weeks before birth) to protect young infants from pertus-
sis (cocoon strategy) [25]. However, only 23% of pregnant
women in a large nationwide cross-sectional survey in
2013 [11] and 22% of household contacts of infants inter-
viewed as part of a large population based telephone
survey in 2012/13 reported having obtained a pertussis
vaccination within the last 10 years, the latter an increase
of 11% from 2009/2010 [26, 27]. In addition, several stud-
ies have shown limited impact of cocooning strategies on
infant pertussis disease burden [28–32].
Pertussis vaccination of pregnant women has recently
been introduced in several countries. Antenatal mater-
nal vaccination is associated with efficient transfer of
pertussis-specific antibodies from mother to infant
[33, 34] and several studies have shown high effect-
iveness ranging from 69 to 95% for preventing pertus-
sis in the first 2–3 months of life [35–43]. Several
systematic reviews [33, 34, 44–46] concluded that ad-
ministration of tetanus, diphtheria, pertussis (Tdap)
vaccine in pregnancy is safe, although the quality of
the evidence in underlying studies is mainly low.
Since late 2016, the summary of product characteris-
tics for two pertussis-containing vaccines available in
Germany were updated with data on the safety
administration in pregnancy; similar updates are
planned for other products [17]. Tdap vaccination of
pregnant women is not yet recommended in
Germany, but STIKO is currently evaluating the evi-
dence for a potential recommendation according to
its standard procedure [47]. In Germany, gynaecolo-
gists in private practice (i.e. all practicing physicians
in the field of Gynaecology and Obstetrics in out-
patient care, as opposed to gynaecologists working in
hospital care) are the primary health care providers
for pregnant women and thus instrumental in provid-
ing maternal vaccinations, which is not the task of
midwives. In view of currently low influenza vaccin-
ation coverage in pregnant women and a possible
STIKO recommendation for pertussis vaccination of
pregnant women, the Robert Koch Institute (RKI)
conducted a survey of gynaecologists in private prac-
tice in collaboration with the German Professional
Association of Gynaecologists (BVF) and their work-
ing group on vaccination. Existing literature on health
care workers’ attitudes about influenza vaccination in preg-
nancy may differ between countries due to heterogeneous
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vaccination programs and health systems, and little is
known regarding attitudes about pertussis vaccination dur-
ing pregnancy. Assessing attitudes and acceptability specif-
ically in gynaecologists, with their role as the main
implementer, is important in view of a potential pertussis
vaccination recommendation. Our goal was to assess
gynaecologists’ attitudes and practices with respect to influ-
enza and pertussis vaccination and to identify perceived
barriers and opportunities for their implementation.
Methods
Study population and questionnaire
Our target population included all gynaecologists in pri-
vate practice. In Germany, every practicing physician
must be affiliated with one of the State Chambers of
Physicians [48]. According to the statistics of the German
Medical Association (BÄK), containing the combined data
of the State Chambers of Physicians, there were 11,500
gynaecologists in private practice in 2016 in Germany [49].
We developed a 24-item questionnaire (Additional file 2)
by focussing on the study aim and taking previous experi-
ence and literature findings into account [50]. After an
internal pre-test by colleagues of the Immunization Unit
at the RKI for comprehensibility and time required (ap-
proximately 8min), the questionnaire was sent to elected
officials of the BVF and their working group on vaccin-
ation (in total approx. 150 persons) in July 2017. In total,
we received feedback from 43 persons. The questionnaire
covered awareness and implementation of current vaccin-
ation recommendations. We also asked about possible
vaccination barriers and what measures gynaecologists
might consider effective for achieving high pertussis vac-
cination coverage in pregnant women in case of a STIKO
recommendation. Additional items covered general vac-
cination practices and demographics. Questions were
mainly closed-ended with yes/no answer options, and we
specified the use of other categories in the results. We
grouped agreement with vaccination barriers into “agree”
(rather or fully agree), “partly agree” and “disagree” (rather
or fully disagree) and suitability of measures into “suitable”
(very suitable and rather suitable), “partly suitable”, “not
suitable” (rather not suitable or not suitable at all) and
“unsure”. Free text comments were permitted to state
additional barriers for influenza or pertussis vaccination
during pregnancy as well as to suggest further measures
to achieve high pertussis vaccination coverage in pregnant
women.
Data collection and sample size calculation
As a way of gaining access to a large proportion of the
target population, the questionnaire was published along
with background information in the 2017 September
edition of the monthly BVF journal Frauenarzt (“Gynae-
cologist”) that is circulated to all its members, including
approximately 8000 gynaecologists in private practice.
Thus, we could potentially reach about 70% of our target
population through the BVF access. The authors are not
aware of differences between gynaecologists in private
practice with and without BVF membership. Through
the collaboration with the BVF and with the goal of
achieving high participation, we were able to additionally
distribute the questionnaire through the BVF@ktuell
newsletter (5164 subscribers), the online platform Gyn-
Netz (1850 subscribers) and the BVF’s federal state
representatives, all of which also addressed only the po-
tentially reachable target population of BVF members. In
order to avoid multiple participation of persons who
may have been invited several times to take part in the
survey, we have expressly pointed out that only one par-
ticipation per person is desired. No incentives were
offered for participation in the survey. A reminder was
published in the October edition of Frauenarzt. Partici-
pants could complete the survey on paper or using the
online platform Voxco (Voxco Version 5.5.1.205). Paper
questionnaires were to be sent to the RKI anonymously
via mail, scanned via e-mail, or by fax. Data collection
was closed on November 6th.
At a confidence level of 95%, the minimum number of
participants needed from the target population of 11,500
gynaecologists to determine a proportion of 50% at an
absolute precision of 5 and 3%, was calculated to be 372
and 977, respectively, using OpenEpi. https://www.open
epi.com/SampleSize/SSPropor.htm
Statistical analysis
Responses of paper questionnaires were double-entered.
In our descriptive analyses we displayed categorical vari-
ables as percentages. To evaluate representativeness we
compared demographic characteristics of our partici-
pants to BÄK statistics on all privately practicing gynae-
cologists. We used the Chi Square Test or Fischer’s
Exact Test to test for associations between categorical
variables and the t-test to compare continuous variables
within categories of a second variable, for influenza and
pertussis vaccination, respectively. We performed strati-
fied analyses to further assess potential associations of
performing vaccination with demographics, other vac-
cination practices and perceived barriers. Moreover,
univariate and multivariate logistic regression analyses
(adjusted for age, sex and region) were conducted to
identify variables associated with the implementation of
influenza and pertussis vaccination in pregnant women,
by comparing gynaecologists who currently do vaccinate
to those who do not, respectively for the two vaccina-
tions. P-values < 0.05 were considered statistically signifi-
cant. We categorized text responses to open questions
by creating keywords and assigning each response. We
performed statistical analysis using Stata® version 14
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(StataCorp, Texas, USA) and used Microsoft Excel
(2010) to create figures.
Results
Response and description of participants
We received 934 questionnaires, 734 (79%) through the
online platform and 200 (21%) paper-based.
Since there was no individual login function for the
online survey, we excluded incomplete questionnaires to
avoid double counting of persons who logged in several
times without completion. Unreadable or duplicate
questionnaires sent by scan or fax were also not taken
into account. As shown in Fig. 1, we were able to include
867 questionnaires in the final analysis. Thus, approxi-
mately 11% of BVF members participated, corresponding
to 8% of all gynaecologists in private practice (Fig. 1).
Compared to all privately practicing gynaecologists
registered with the BÄK, a higher proportion of survey
participants was female, aged 50–59 years and from east-
ern federal states; a lower proportion was 60 years or
older and from western federal states (Table 1). At the
federal state level, gynaecologists from Bavaria, North
Rhine-Westphalia and Hamburg were underrepresented
in our survey, while those from Saarland, Hesse and
Saxony were overrepresented (Fig. 2). Participants had
spent a median of 15 years in private practice (IQR: 9–
22). When asked about their own influenza vaccination
practices, 70.6% reported annual vaccination, 16.6%
occasional vaccination and 12.8% never obtaining vac-
cination. The proportion of gynaecologists reporting
regular influenza vaccination was higher in eastern than
western federal states (82.1% vs. 68.1%, p = 0.004), but
did not differ according to age, sex or years of work
experience.
Influenza vaccination in gynaecological practices
Current practice of influenza vaccination during pregnancy
Almost all respondents were aware of the influenza vac-
cination recommendation for pregnant women (99.2%)
and most stated recommending (95.4%) and performing
(91.4%) it. Although the majority reported informing
their pregnant patients about this recommendation
(98.5%), 8.6% of them informed on patient request only.
Compared to gynaecologists who actively informed
patients, the latter were significantly less likely to state
recommending (65.3% vs. 99.1%, p < 0.001) and perform-
ing vaccination (62.2% vs. 95.1%, p < 0.001) or to provide
information material on influenza vaccination during
pregnancy in their practice (18.9% vs. 65.0%, p < 0.001).
Among gynaecologists who offered their pregnant pa-
tients influenza vaccination, 44.2% stated that ≥50%
women accepted vaccination (Fig. 6). This proportion
was higher among gynaecologists who actively informed
pregnant women (47.0% vs. 3.9%, p < 0.001). While we
did not find a significant association between recom-
mending or performing influenza vaccination and sex,
age, years of work experience, or geographical region,
there was a strong association with participating gynae-
cologists’ own influenza vaccination practices (Fig. 3;
Additional file 1: Table S1).
Perceived barriers for influenza vaccination during
pregnancy
Participants were asked if six possible barriers for influ-
enza vaccination of pregnant women applied to them, as
Fig. 1 Response of privately practicing gynaecologists in Germany for participation in our survey
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outlined in Fig. 4 and listed in Additional file 1: Table S1.
They had the opportunity to state additional barriers.
Only a small proportion acknowledged the listed items to
be vaccination barriers, but those who did were signifi-
cantly less likely to report vaccinating their pregnant pa-
tients (Fig. 4). This was confirmed in both univariate and
multivariate logistic regression analysis (Additional file 1:
Table S1). Overall, time and effort required to inform
pregnant women was most often perceived as a barrier
(26.4% at least partly agreed). However, physicians who
perceived difficulties in integrating vaccination into rou-
tine practice processes as a barrier were least likely to re-
port actually performing vaccination (Fig. 4). The
exclusive availability of large package sizes for influenza





Characteristics Frequency Percent Percent
Sex 856
Female 653 76.3 66.3
Male 203 23.7 33.7
Age (in years) 842
≤49 277 32.9 31.8
50–59 419 49.8 41.1
≥60 146 17.3 27.1
Work experience in gynaecological practice (in years) 854
≤9 217 25.4 –
9–19 346 40.5 –
≥20 291 34.1 –
Geographical region 849
Easta 145 17.1 13.3
Westb 704 82.9 86.7
Abbreviations: BÄK German Medical Association (Bundesärztekammer)
aEast: Brandenburg, Mecklenburg Western Pomerania, Saxony, Saxony-Anhalt, Thuringia
bWest: Baden-Wuerttemberg, Bavaria, Berlin, Bremen, Hamburg, Hesse, Lower Saxony, North Rhine-Westphalia, Rhineland Palatinate, Saarland, Schleswig-Holstein
Missing values were not considered, thus the number of participants differs slightly between variables
Fig. 2 Distribution of survey participants versus all privately practicing gynaecologists registered with BÄK across federal states
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vaccines was mentioned as one such factor in additional
comments (Additional file 1: Table S2). Billing regulations
are defined at the federal state level by the Association of
Statutory Health Insurance Practitioners (ASHIP). Of our
participants, only 7.8% agreed that billing restrictions were
an obstacle for influenza vaccination during pregnancy, but
this proportion was higher among gynaecologists affiliated
with the ASHIP Bavaria (13.6%), ASHIP Saxony (19.0%)
and ASHIP Rhineland Palatinate (26.3%). Among partici-
pants who perceived ASHIP restrictions to be a vaccination
barrier, the proportion reporting to recommend influenza
vaccination to pregnant patients was lower (87.7% vs. 96.1%
among all others, p = 0.002), and the proportion reporting
to perform vaccination lower still (69.7% vs. 93.0%, among
all others p < 0.001; Additional file 1: Table S1). Physicians
who did not inform or only informed pregnant patients of
Fig. 3 Proportion of gynaecologists who stated recommending, actively informing their pregnant patients or performing influenza and pertussis
vaccination, according to their own influenza vaccination practices
Fig. 4 Proportion of gynaecologists performing influenza vaccination in pregnant women, in relation to their agreement with possible barriers
for implementation
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the vaccination recommendation upon request (n = 87)
more often agreed that the time and effort required for
consultation constituted a barrier for vaccination (44.2% vs.
8.5% among all others, p < 0.001). In additional comments
(Additional file 1: Table S2), some gynaecologists indicated
that pregnant women often held misconceptions about
vaccination during pregnancy which frequently led to vac-
cination refusal, despite time-consuming consultation.
They also claimed that remuneration was insufficient for
the time and effort expended. Gynaecologists who stated
to not recommend influenza vaccination (n = 38) more
frequently agreed that limited effectiveness (50.0% vs. 2.6%
among all others, p < 0.001) and safety concerns (57.9%
vs. 3.2% among all others, p < 0.001) were barriers.
To a lesser extent, this also held for participants
who reported never obtaining influenza vaccination
themselves, among whom a higher proportion agreed
that limited effectiveness (21.2% vs. 2.6% among all
others, p < 0.001), safety concerns (22.1% vs. 3.4%
among all others, p < 0.001) and low perceived risk
for severe disease in pregnant women (20.2% vs.
4.1% among all others, p < 0.001) were barriers for
influenza vaccination of pregnant women.
Pertussis vaccination in gynaecological practices
Current practice of present pertussis vaccination
recommendations
Most gynaecologists were aware of the current pertus-
sis vaccination recommendations targeting women of
child-bearing age and close infant contacts (Fig. 5).
Although the majority (86.7%) stated recommending
pertussis vaccination to close infant contacts, only
53.7% stated performing this in their practice. Over
one third (39.4%) agreed that billing restrictions for
vaccination of infant contacts through ASHIP regula-
tions were a barrier. This proportion was higher in
western than eastern federal states (42.0% vs. 27.7%,
p = 0.001) and highest among gynaecologists affiliated
with ASHIP Baden-Württemberg (55.1%), Bavaria
(72.0%) and Berlin (72.3%). Although these physicians
stated recommending vaccination of close contacts as
often as others, they were less likely to report per-
forming this in their practices (26.1% vs. 72.5%
among all others, p < 0.001).
Current practice of pertussis vaccination during pregnancy
Of participating gynaecologists, 698 (82.1%) stated
informing their patients about the possibility of pertussis
vaccination during pregnancy. Of these, 18.6% informed
upon patient request only. Physicians who obtained an-
nual influenza vaccination were more likely to inform
pregnant women about pertussis vaccination (Fig. 3).
Over half of participants (59.4%) reported already vac-
cinating pregnant women against pertussis despite a
lacking STIKO recommendation. This proportion was
non-significantly higher in eastern federal states (64.3%
vs. 58.2%, p = 0.18), and highest among participants from
Saxony at 76.3%. Physicians who actively informed pa-
tients were more likely to report vaccinating than those
who did not or only upon patient request (82.4% vs.
12.9%, p < 0.001; Additional file 1: Table S3). Pertussis
vaccination of pregnant patients was not significantly as-
sociated with age, work experience or region overall
(Additional file 1: Table S3). Male gynaecologists stated
more frequently to perform pertussis vaccination during
pregnancy compared to female gynaecologists, which
was statistically significant in western (67.1% vs. 55.4%,
p = 0.007), but not in eastern federal states (68.0% vs.
63.6%, p = 0.67). Physicians who stated implementing
cocoon strategy recommendations (Additional file 1:
Table S3) and those who obtained influenza vaccination
themselves were more likely to report performing per-
tussis vaccination in pregnancy (Fig. 3; Additional file 1:
Table S3). About a quarter (23.9%) of participants re-
ported that only < 10% and over a third (37.0%) that
≥50% of pregnant patients accepted their pertussis vac-
cination offer (Fig. 6). Among physicians who did not
actively inform patients, fewer reported an acceptance of
≥50% (5.6% vs. 39.4%, p < 0.001).
Fig. 5 Proportion of gynaecologists who stated being aware of, recommending and performing pertussis vaccination for the following groups, if
no vaccination was obtained in the previous 10 years: women of child-bearing age, women postpartum and close infant contacts
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Perceived barriers for pertussis vaccination during
pregnancy
As for influenza vaccination, participants were asked if
seven possible barriers for pertussis vaccination of preg-
nant women applied to them, as shown in Fig. 7 and
Additional file 1: Table S3. They were also asked if add-
itional barriers applied. Overall, a higher proportion of
gynaecologists agreed that barriers existed for pertussis
compared to influenza vaccination during pregnancy,
and those who did were less likely to report informing
about or performing pertussis vaccination. This associ-
ation was confirmed in both univariate and multivariate
logistic regression analysis for all proposed barriers
except for low perceived disease severity in infants (Add-
itional file 1: Table S3). Participants most often agreed
that the lack of a STIKO recommendation was a barrier
for pertussis vaccination of pregnant patients (40.1%:
67.8% among physicians who reported not yet vaccinat-
ing pregnant women vs. 21.6% among all others (p <
0.001)), followed by lack of a pertussis-only vaccine
(32.2%) and the time and effort needed to inform pa-
tients (19.9%). Physicians who agreed that the lack of a
STIKO recommendation, limited vaccine effectiveness,
safety concerns and logistical difficulties were vaccin-
ation barriers were least likely to state performing per-
tussis vaccination (Fig. 7; Additional file 1: Table S3). As
for influenza vaccination, physicians commented that
fear or scepticism of vaccination during pregnancy
often led to refusal, despite thorough explanation of
benefits (Additional file 1: Table S4). Physicians also
commented that the lack of a pertussis-only vaccine
required additional explanation and some thought
recent vaccination with a tetanus-containing vaccine
was problematic. Other comments addressed limited
availability of pertussis-containing vaccines, concerns re-
garding possible long-term effects on the unborn child
and fear of potential legal consequences (Additional file 1:
Table S4).
The majority of participants not yet vaccinating
against pertussis during pregnancy stated they would
routinely recommend and perform pertussis vaccination
if STIKO were to recommend this (86.5%). However,
this proportion was significantly lower among those who
agreed that limited effectiveness (56.3%), safety concerns
(72.8%) and a low risk posed by infant pertussis (27.3%)
were vaccination barriers.
Measures for attaining high pertussis vaccination coverage
in pregnant women
Participants were asked to rate the suitability of 8 pos-
sible measures for attaining a high pertussis vaccination
coverage in pregnant women in the case of a STIKO rec-
ommendation (Fig. 8). They could state additional mea-
sures. Almost all participants (95.2%) considered the
integration of the recommendation into the maternity
record issued to all women for the documentation of
health care during pregnancy a suitable measure to at-
tain high pertussis vaccination coverage. The majority
also rated information campaigns and material such as
flyers or posters for practices suitable (88.7 and 86.6%,
respectively). This also held for educating midwives on
vaccinations, improved remuneration for informing
about and performing vaccinations, as well as an advo-
cating position by the professional association for gynae-
cologists (80.3 to 82.0%). Providing information material
for physicians and vaccination reminders through the
practice software were rated suitable less frequently
(74.8 and 60.7%, respectively). In additional comments,
participants proposed better information and continuing
education of health care professionals, including general
practitioners, midwives and practice support staff (Add-
itional file 1: Table S5). Many comments addressed how
Fig. 6 Distribution of gynaecologists’ estimation for the acceptance of influenza and pertussis vaccination of pregnant women, respectively. For
example, 9.6% of gynaecologists in our survey reported that less than 10% of their pregnant patients accepted an influenza vaccination following
a vaccination offer
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best to inform pregnant patients. Using a range of media
to convey positive messages, including non-scientific
media such as TV, campaigns, the internet, social
media/apps and educational settings, was suggested.
Others proposed removing various prior stated barriers,
the use of incentives and vaccination reminders. Some
comments related to improving vaccination coverage in
general or that of close contacts, e.g. through mandatory
vaccination.
Discussion
This is the first survey in Germany to assess attitudes
towards and performance of pertussis vaccination to
protect mothers and their infants among privately
practicing gynaecologists. Although a survey on attitudes
towards and recommendation of influenza vaccination
for pregnant women was performed previously [50], this
did not assess active informing and actual performance
of vaccination.
Attitudes towards influenza and pertussis vaccination
among gynaecologists
The majority of gynaecologists participating in our
survey was aware and supportive of current recommen-
dations for influenza and pertussis vaccination for preg-
nant women or, in case of pertussis, their contacts or
women of child-bearing age. Strong support for influ-
enza vaccination in pregnancy was also reported in a
previous German survey [50]. However, this is not
Fig. 7 Proportion of gynaecologists performing pertussis vaccination in pregnant women, in relation to their agreement with possible barriers
for implementation
Fig. 8 Gynaecologists’ ratings of the suitability of suggested measures to attain high pertussis vaccination coverage in pregnant
women (n = 849–856)
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reflected in high vaccination uptake by pregnant women
in Germany [10–13]. In another recent German survey,
pregnant women rated gynaecologists’ attitudes towards
vaccination in pregnancy as only moderate; only 54% of
surveyed women were aware of the recommendation
themselves and 44% stated this as the reason for not
having obtained the vaccine [13]. Possible explanations
for these discrepancies include poor communication be-
tween physicians and patients or socially desirable
responses in the surveys. For instance, in a recent US
study all participating gynaecologists stated recommend-
ing influenza vaccination, yet only 85% of their pregnant
patients stated having received a recommendation [51].
However, our low response and biased participation
likely also play an important role.
Gynaecologists in our survey reported higher accept-
ance for influenza compared to pertussis vaccination
among pregnant women (Fig. 6). In countries that have
implemented pertussis vaccination in pregnancy, in con-
trast, acceptance was reported to be higher for pertussis
vaccination [52, 53]. We suspect this difference could be
due to the lack of an official recommendation and subse-
quent lower awareness for pertussis vaccination in preg-
nancy at the time of our survey. However, our and other
findings show that the cocoon strategy currently in place
to prevent pertussis infections in infants also lacks im-
plementation [11]. Bödeker et al. showed that pregnant
women in Germany rated the risk of pertussis infection
for children low [13]. This highlights the importance
that awareness about pertussis vaccination recommenda-
tions need to be increased in both gynaecologists and
the targeted population of recommendations.
Determinants and barriers for offering vaccination
The Complacency, Convenience and Confidence (“3Cs”)
model by the SAGE working group describes vaccine
hesitancy as a complex interplay of many different fac-
tors [54]. While the model was developed primarily to
explain vaccine hesitancy among target groups for vac-
cination, the 3Cs can also be applied to vaccinators and
we highlight this in the subsequent discussion.
Physicians who obtained influenza vaccination them-
selves were far more likely to actively inform about and
vaccinate their pregnant patients against both influenza
and pertussis in our survey, as also observed by others
[50, 52, 55, 56]. In our survey, concerns of limited effect-
iveness and safety were more common among gynaecol-
ogists who reported not obtaining annual influenza
vaccination. Thus, physicians’ own vaccination practices
seem to reflect their confidence in vaccination [55].
Additionally, those who obtained annual influenza vac-
cination were more likely to provide information mater-
ial on vaccination in their practice. Not surprisingly, for
pertussis, the lack of a STIKO recommendation was
perceived as a barrier for performing pertussis vaccin-
ation by a high proportion of participants. Indeed, the
majority of participants said they would offer this vac-
cination to pregnant patients if recommended by the
STIKO. This suggests a fundamental acceptance of Tdap
vaccination and trust in STIKO decisions. Despite these
encouraging findings among our participants, vaccine
hesitancy was identified among a minority (likely to be
larger among non-participating gynaecologists) who per-
ceived low vaccine effectiveness, vaccine safety concerns
or (the misconception) that influenza or pertussis pose
only a low risk for pregnant women and infants to be
vaccination barriers. However, the latter – a complacency-
related barrier – was significantly associated only with per-
forming influenza but not pertussis vaccination (Additional
file 1: Table S1 and S3). These findings underline the im-
portance of a transparent decision process on the part of
the STIKO and the need to inform health care professionals
about the evidence for vaccination recommendations, also
to address doubts or misbeliefs that lead to hesitancy.
Convenience-related barriers included the time and
effort needed to inform pregnant women about vaccin-
ation, which were frequently perceived as a vaccination
barrier, especially among gynaecologists who reported
they informed only upon patient request. In additional
comments, participants related this to scepticism regard-
ing vaccination on the part of pregnant women. Simi-
larly, a recent German survey found that pregnant
women commonly believed influenza vaccination was
more harmful than influenza infection [13]. Some partic-
ipants claimed that women refused vaccination despite
extensive consultation. This could lead to frustration
and decrease motivation to recommend and perform
vaccination. A few participants commented that negative
media coverage led to low vaccination acceptance, and
this is corroborated by a representative survey that
found pregnant women refused vaccination due to vac-
cine-critical reports or advice from family and friends
[10]. Another study found that a high proportion of eld-
erly participants (35%) reported their decision to obtain
influenza vaccination was based on the recommendation
of family or friends [57].
Only a small proportion of gynaecologists perceived
the integration of influenza and pertussis vaccination
into their practice procedures to be barriers. However,
this was associated with a much lower likelihood of
performing the respective vaccinations in pregnant
women and is likely to be more common among non-
participating gynaecologists. Thus, convenience mea-
sures such as ensuring availability of smaller package
sizes and prevention of vaccine shortages could facilitate
implementation of vaccination. Remuneration is another
convenience-related factor, and gynaecologists who re-
ported billing restrictions through ASHIP regulations for
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influenza vaccination in pregnant women or, more com-
monly, pertussis vaccination in close infant contacts
were less likely to state performing vaccinations. This
may contribute to the poor implementation of the
cocoon strategy. While billing restrictions had a large
impact on performing vaccination, they had minimal
(influenza) or no impact (pertussis) on recommending
vaccination. However, uptake of influenza vaccination in
pregnant women is much lower if only recommended,
but not performed [58].
Over a third of our participants perceived the lack of a
pertussis-only vaccine to be a barrier to some extent,
with a resultant lower likelihood of performing the vac-
cination. Availability of such a vaccine as recently
licensed in Thailand [59] and studied in Switzerland [60]
would therefore likely additionally increase acceptance
and coverage [61].
Possible measures to achieve high vaccination uptake in
pregnant women
Our findings suggest several approaches to improve
implementation of vaccination recommendations by
gynaecologists and to support them in their important
role as vaccination advocates.
Almost all participants thought the inclusion of vac-
cination recommendations in the maternity record held
by pregnant women would help attain high pertussis
vaccination coverage. The maternity record acts as an
inventory for the documentation of recommended tests
and procedures in the ante-, peri- and postnatal period.
In a recent survey on acceptance of vaccination in
England, pregnant women proposed such a checklist to
ensure reception of all recommended aspects of preg-
nancy care, including vaccination [62]. The inclusion of
vaccination recommendations is already under discus-
sion with the Federal Joint Committee (G-BA) respon-
sible for issuing the maternity record.
In Germany, remuneration for vaccination is currently
linked to the administration of a vaccination. Some par-
ticipants in our survey felt compensation for vaccination
services was insufficient, particularly the lack of compen-
sation for vaccination consultation not linked to admin-
istration of vaccines. In keeping with this, the majority
of participants agreed that improved remuneration
would be an appropriate measure to achieve high pertus-
sis vaccination coverage.
On the other hand, only 61% of participants in our
survey thought recall systems were a useful measure, al-
though they have shown to be efficient at increasing vac-
cination information, acceptance and coverage [63–65].
A possible explanation may be that pregnancy is not a
regularly recurrent event and thus, implementation of
software reminders may be difficult. Further reasons for
this are unclear and should be investigated.
Our findings strongly suggest that, in view of gynae-
cologists, public knowledge and awareness need to be in-
creased for both influenza and – in case of a STIKO
recommendation – pertussis vaccination in pregnancy.
A large majority of participants rated public campaigns
and information material for pregnant patients in prac-
tices as suitable measures for achieving high pertussis
vaccination coverage. Using social media or apps was
also suggested. Such approaches may reduce concerns
and hesitancy in pregnant women and could help fa-
cilitate consultation on vaccination by physicians, as
also suggested by results of a survey among paediatri-
cians [66].
Physicians who took the initiative to actively inform
pregnant women about vaccination were less likely to
doubt vaccine effectiveness or have safety concerns and
more likely to obtain vaccination themselves or to report
high uptake among their pregnant patients. A recent EU
report on vaccine confidence points out that confidence
in vaccination is crucial to achieve high vaccination
coverage [67]. Thus, increasing knowledge and therefore
confidence in these vaccinations among gynaecologists
appears crucial in achieving high influenza and, in case
of a recommendation, pertussis vaccination uptake
among pregnant women. Three quarters of participants
thought that information material specifically for physi-
cians, including general practitioners, could help attain
high vaccination coverage. While this seems plausible –
particularly for a new vaccination recommendation
targeting a vulnerable group such as pregnant patients –
we are unaware of evidence showing that provider edu-
cation improves vaccination uptake. Such material
should address the benefits and limited risks of recom-
mended vaccinations, as well as harms due to vaccine
preventable diseases. This could be provided by the
STIKO, for instance through its vaccination app, as well
as through professional associations such as the BVF.
Over half the participants thought education of mid-
wives could also encourage vaccination uptake. This is
supported by other studies: In a German survey, preg-
nant women rated midwives’ attitudes towards vaccin-
ation in pregnancy as only moderate [13]. Others
showed that, compared to gynaecologists, midwives were
less aware of vaccination recommendations [68] and had
more safety concerns about vaccination during preg-
nancy [69]. Engaging midwives and providing informa-
tion based on their needs was found to be effective [70],
and involving them in an immunization programme led
to higher vaccination coverage in pregnant women in
Australia [71]. Although midwives are not involved in
delivering vaccination in Germany, they play a signifi-
cant role in antenatal and postnatal care and thus, their
support of vaccination recommendations is important
for a successful implementation.
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Limitations
Our survey had several limitations, the most important
being the low response of only 11%. This was despite
our invitation to participate through various channels to
maximize awareness for the survey and to address as
many members of the target population as possible,
accepting that some might be contacted more than once,
and despite offering multiple response options. A recent
survey on influenza and HPV vaccination achieved a
slightly higher response of 20% by directly sending ques-
tionnaires to privately practicing gynaecologists [50].
Although about 70% of privately practicing gynaecolo-
gists receive the BVF journal Frauenarzt, the proportion
of active readers may be lower. Nonetheless, demo-
graphic characteristics did not differ markedly between
survey participants and all privately practicing gynaecol-
ogists. Although female gynaecologists were slightly
over- and the oldest group underrepresented, sex and
age did not have a large impact on our findings. Partici-
pation was higher among gynaecologists from eastern
federal states, where vaccination acceptance and cover-
age has consistently been higher for most vaccines, both
in physicians and the general population [27, 50, 72–74].
This also held for Saxony, where pertussis vaccination in
pregnancy is already recommended by a state-based
immunization technical advisory group. To account for
these differences, rooted in very different development
of vaccination regulations in the two parts of Germany
prior to re-unification in 1989 [50, 75], we compared
these regions in our analyses. Influenza vaccination
coverage among gynaecologists in our survey (70.6%)
was higher than reported from a telephone survey of
gynaecologists in private practice (50.4%) [73]. However,
in a more recent survey that used self-administered
questionnaires, reported coverage was similar at 72.2%
[50]. Nonetheless, it seems likely that highly motivated
gynaecologists committed to vaccination were over-
represented in our survey. This likely explains the high
proportion of participants reporting pertussis vaccin-
ation of their pregnant patients despite the lacking
STIKO recommendation. Therefore, non-participating
gynaecologists may be more likely to question effective-
ness and safety of vaccines in pregnancy or to consider
the efforts required to implement vaccination – related
to information of patients, logistics or to remuneration
– as not worthwhile.
As discussed above, our findings identify important bar-
riers for the implementation of influenza and pertussis
vaccination during pregnancy. Thus, findings provide infor-
mation on how implementation of current vaccination
recommendations by gynaecologists could be improved
and high pertussis vaccination uptake among pregnant
women could be achieved, should STIKO recommend this
in the future.
Conclusions
Despite the limitations of our survey, we gained valuable
insight into current vaccination practices of gynaecologists
in private practice in Germany. The majority of our
participants stated their willingness to offer pertussis
vaccination to their pregnant patients should this be rec-
ommended by the STIKO. Our results suggest the imple-
mentation of vaccination recommendations targeting
diseases in mothers and their infants is associated with
physicians’ own vaccination uptake and an active ap-
proach to vaccinations, which are both likely linked to
their confidence in vaccination. Therefore, we recommend
enhancing the focus and inclusion of vaccination in con-
tinuing medical education activities to counter potential
uncertainties with available scientific evidence for vaccine
effectiveness and safety and to emphasize and support
physicians’ role as vaccination advocates. The integration
of antenatal vaccination recommendations into the mater-
nal record as part of official standard procedures during
pregnancy care would serve as an important reminder for
both physicians and pregnant women. Means to remove
barriers such as billing restrictions and logistical chal-
lenges should also be sought. Gynaecologists themselves
stressed the importance of increasing patient awareness
and dispelling vaccine scepticism through the use of a
wide range of media including information material in
practices.
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